The Latest Analyst Ratings for Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Mirum Pharmaceuticals (NASDAQ:MIRM) stock, with all 5 giving bullish ratings. The company has an average 12-month price target of $65.0, representing a 21.69% decrease from the previous average price target of $83.00.
June 15, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals (NASDAQ:MIRM) received 5 bullish ratings from analysts over the past 3 months. The average 12-month price target is $65.0, down 21.69% from the previous target.
The unanimous bullish ratings from 5 analysts indicate a positive outlook for Mirum Pharmaceuticals. However, the decrease in the average 12-month price target suggests that the stock's growth potential may be lower than previously anticipated. This could still lead to a short-term increase in the stock price, but at a slower pace.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100